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Abstract
The role of tumor necrosis factor (TNF) as an immune mediator has long been appreciated but its
function in the brain is still unclear. TNF receptor 1 (TNFR1) is expressed in most cell types, and
can be activated by binding of either soluble TNF (solTNF) or transmembrane TNF (tmTNF), with
a preference for solTNF; whereas TNFR2 is expressed primarily by microglia and endothelial cells
and is preferentially activated by tmTNF. Elevation of solTNF is a hallmark of acute and chronic
neuroinflammation as well as a number of neurodegenerative conditions including ischemic stroke,
Alzheimer's (AD), Parkinson's (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis
(MS). The presence of this potent inflammatory factor at sites of injury implicates it as a mediator
of neuronal damage and disease pathogenesis, making TNF an attractive target for therapeutic
development to treat acute and chronic neurodegenerative conditions. However, new and old
observations from animal models and clinical trials reviewed here suggest solTNF and tmTNF exert
different functions under normal and pathological conditions in the CNS. A potential role for TNF
in synaptic scaling and hippocampal neurogenesis demonstrated by recent studies suggest additional
in-depth mechanistic studies are warranted to delineate the distinct functions of the two TNF
ligands in different parts of the brain prior to large-scale development of anti-TNF therapies in the
CNS. If inactivation of TNF-dependent inflammation in the brain is warranted by additional pre-
clinical studies, selective targeting of TNFR1-mediated signaling while sparing TNFR2 activation
may lessen adverse effects of anti-TNF therapies in the CNS.
Introduction
The potent pro-inflammatory cytokine Tumor necrosis
factor (TNF) is a member of the TNF superfamily of lig-
ands, many of which promote inflammatory signaling [1-
3]. TNF is synthesized as a monomeric type-2 transmem-
brane protein (tmTNF) that is inserted into the membrane
as a homotrimer and cleaved by the matrix metallopro-
tease TNF alpha converting enzyme (TACE; ADAM17) to
a 51 kDa soluble circulating trimer (solTNF); both tmTNF
and solTNF are biologically active (reviewed in [4-6]), and
can be synthesized in the central nervous system (CNS) by
microglia, astrocytes, and some populations of neurons
[7-9]. The balance between tmTNF and solTNF signaling
is influenced by cell type, activation status of the cell, the
stimulus eliciting TNF production, TACE activity, and
expression of endogenous TACE inhibitors leading to
divergent TNF-mediated effects on cellular viability
[10,11].
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TNF receptors
TNF receptor 1 (TNFR1, Tnfrsf1a) and TNF receptor 2
(TNFR2, Tnfrsf1b) are membrane glycoprotein receptors
that specifically bind TNF and homotrimers of lympho-
toxin A, but the two receptors differ in their expression
profiles, ligand affinity, cytoplasmic tail structure, and
downstream signaling pathway activation (reviewed in
[12]). Signaling of TNF through TNFRs requires that
receptors preassemble on the cell membrane as trimers
prior to ligand binding, this trimerization occurs through
the intracellular cytoplasmic tail of the receptors and trim-
ers are composed of like receptors due to the divergent
sequence of their intracellular domains [13,14]. TNFR1 is
expressed in most cell types, and can be activated by bind-
ing of either solTNF or tmTNF, with a preference for
solTNF; whereas TNFR2 is expressed primarily by cells of
the immune system (including microglia) and by
endothelial cells, and is preferentially activated by tmTNF
[15,16].
Intracellular signaling pathways activated by TNF 
receptors
TNF signaling through TNFR1 and TNFR2 can elicit a vari-
ety of cellular responses depending on many factors
including the metabolic state of the cell and the adaptor
proteins present in the cell. These differences then influ-
ence the activation of a number of intracellular signaling
pathways including nuclear factor kappa-B (NF-κB), p38,
c-jun N-terminal kinase (JNK), and the ceramide/sphin-
gomyelinase signaling pathway, resulting in a number of
responses including inflammation, proliferation, cell
migration, apoptosis, and necrosis [17-20].
TNFR1-mediated signaling
SolTNF signaling is thought to elicit its biological effects
primarily through TNFR1 activation. TNFR1 contains a
cytoplasmic death domain (DD) characteristic of many
members of the TNF superfamily that permits the assem-
bly of the TNFR1 signaling complex through the dissocia-
tion of silencer of death domains (SODD) and
subsequent binding of TNF receptor associated death
domain (TRADD) [21,22]. Binding of TRADD then
allows the recruitment of other adaptor proteins includ-
ing receptor interacting protein (RIP) and TNF receptor
associated factor 2 (TRAF2) [23-26]. This complex then
leads to RIP-dependent activation of NFκB signaling to
initiate pro-survival signaling, cellular proliferation, and
cytokine production. This membrane associated complex
of ligand-engaged TNFR1 with TRADD, TRAF2, and RIP
also recruits cellular inhibitor of apoptosis proteins 1 and
2 (cIAP 1,2) resulting in activation of ERK, JNK, p38 MAP
kinase, and ceramide/sphingomyelinase pathways [27-
30]. The kinetics of JNK activation is particularly impor-
tant in determining the functional outcome of a TNF sig-
nal. Acute, transient TNF-induced JNK activation, which is
cytoprotective, results from TAK1-dependent phosphor-
ylation [31], whereas sustained JNK activation leading to
caspase-dependent apoptosis depends upon JNK phos-
phorylation by apoptosis signal-regulating kinase 1
(ASK1) [32]. Knock-in mice expressing mutant TNF that is
no longer a substrate for TACE cleavage (and therefore
remains membrane bound) have demonstrated solTNF to
be the primary mediator of TNF-dependent inflammatory
responses. In these transgenic mice, lymphoid organ
development is relatively normal (with the exception of
primary B cell follicles), but the initiation of autoimmune
pathology is severely compromised [33].
In addition to TNFR1-induced activation of stress-induced
kinase signaling in contributing to apoptotic signaling,
TNFR1 can be internalized after TNF binding and this
leads to dissociation of the TRADD/TRAF2/RIP complex
and association of Fas-associated DD (FADD), recruit-
ment of pro-caspase 8, and formation of the death-induc-
ing signaling complex (DISC), triggering activation of the
executioner caspases through the extrinsic apoptosis path-
way [34,35]. Caspase-8, combined with its ability to
induce apoptosis through the extrinsic pathway, also trig-
gers the intrinsic apoptosis pathway by cleaving the pro-
apoptotic Bcl-2 family members Bax and Bid to initiate
mitochondrial-induced apoptosis [36-38]. The complex-
ity of TNFR1-mediated signaling is what allows many
divergent (ie, proliferation, activation, apoptosis) out-
comes to occur as a result of TNF signaling and contrib-
utes to the difficulties inherent with and the side effects
resulting from broad TNF signaling inhibition, particu-
larly in areas including the CNS where TNF signaling has
been demonstrated to be functionally important for
homeostatic process as discussed in the sections below.
TNFR2-mediated signaling
TNFR2 is restricted to expression in endothelial, hemato-
poetic, and some neuronal populations and displays pref-
erential binding to tmTNF, both of these characteristic are
likely to result in fewer biological effects compared to
those mediated by TNFR1-dependent signaling [16]. Sig-
naling through TNFR2 activates inflammatory and pro-
survival signaling pathways through recruitment of TRAF1
and TRAF2 adaptor proteins and subsequent activation of
cIAPs and the NF-κB pathway [39-41]. TNFR2 has also
been shown to activate phosphatidylinositol 3-kinase-
dependent signaling to promote neuron survival [42,43].
TNFR2 can promote TNFR1 signaling by enhancing the
association between solTNF and TNFR1 via a ligand pass-
ing mechanism, and it has been suggested that this ligand
passing is the primary contribution of TNFR2 to TNF-
mediated signaling in contrast to direct signaling pathway
activation through adaptor protein association with the
intracellular domain of TNFR2 [44]. TNFR2 does not con-
tain a DD, and thus, unlike signaling through TNFR1,Journal of Neuroinflammation 2008, 5:45 http://www.jneuroinflammation.com/content/5/1/45
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TNFR2 activation does not directly lead to caspase activa-
tion. Overall, TNFR2 activation is believed to initiate pri-
marily pro-inflammatory and pro-survival signaling.
Reverse signaling through transmembrane TNF
Upon receptor binding, tmTNF has been demonstrated to
initiate intracellular signaling in the tmTNF-expressing
cell [20,45]. This signaling is mediated, at least in part,
through casein kinase 1 phosphorylation of the cytoplam-
sic tail of TNFR2 resulting in increased intracellular cal-
cium levels and activation of p38 and MAP kinase
pathways [46-48]. Another type of reverse signaling
though tmTNF is possible; after release of solTNF by
TACE, the TNF intracellular domain (TNF-ICD) can be
released into the cell through regulated intramembrane
proteolysis by signal peptide peptidase-like proteases
where it is trafficked to the nucleus by virtue of a nuclear
localization signal resulting in increased production of
pro-inflammatory cytokines [49-51]. A detailed under-
standing of the signaling that occurs through tmTNF is
still underway and the in vivo significance of these reverse
signaling pathways remains to be established.
TNF signaling in the brain
TNF signaling has been shown to have several important
functions within the CNS [52] including injury-mediated
microglial and astrocyte activation, and regulation of
blood brain barrier permeability, febrile responses, gluta-
matergic transmission, and synaptic plasticity and scaling
[53-58]. Excitatory synapse scaling resulting from activity
blockade has been shown to be mediated by TNF-depend-
ent increases in AMPA receptors at the cell surface and
decreases in GABAA receptor cell surface expression, sug-
gesting that TNF may control synaptic strength at excita-
tory synapses by increasing excitatory synaptic
transmission and reducing inhibitory transmission
[57,59,60]. TNF was demonstrated to increase the mean
frequency of miniature excitatory postsynaptic currents
(mEPSCs) [57,59]. In addition TNF has been shown to
increase mEPSC amplitude and decrease mIPSC (minia-
ture inhibitory postsynaptic currents) amplitude [60].
Pharmacologically, TNFR or anti-TNF antibody treatment
could prevent basal and tetrototoxin-induced increases in
surface expression of AMPA receptors as well as increases
in mEPSC amplitude and decreases in mIPSC amplitude,
further supporting solTNF as an important mediator of
synaptic scaling [57,59]. Synaptic scaling was also exam-
ined in hippocampal cultures from TNF deficient mice
and chronic activity blockade did not result in increased
mEPSC amplitude which is seen in wildtype cultures con-
firming the TNF dependence of this increase [59].
The function of TNF signaling through TNFR1 and TNFR2
in the hippocampus and cortex has not been fully eluci-
dated. On the one hand, TNF appears to regulate hippoc-
ampal neuronal development as TNF-deficient mice
display accelerated maturation of the dentate gyrus region
and smaller dendritic trees in the hippocampus [61]. In
contrast, TNF can potentiate excitotoxicity by two mecha-
nisms. In combination with sub-threshold glutamate lev-
els, TNF can potentiate glutamate excitotoxicity directly
through activation of glutamate-NMDA receptors [62]
and localization of AMPA receptors to synapses [63-65],
and indirectly by inhibiting glial glutamate transporters
on astrocytes [66]. However, findings that suggest TNFR2
signaling protects against excitotoxicity have also been
reported. Specifically, cortical neurons from mice that
overexpress TNF in the CNS were protected from gluta-
mate toxicity as were wildtype and TNFR1-deficient mice
pretreated with TNF or agonistic TNFR2 antibodies; con-
sistent with those findings, neurons derived from TNFR2-
deficient mice were susceptible to both TNF and gluta-
mate-induced death [43]. In these studies, protein kinase
B/Akt dependent activation of NFκB was necessary for
neuronal survival after glutamate exposure [43].
Genetic manipulation of TNF or TNF receptors in mouse
models of disease have provided valuable insight into the
biological roles of TNF in the CNS [52]. Elevated levels of
TNF are evident in a large number of neurological disor-
ders including ischemia [67,68], traumatic brain injury
[69], multiple sclerosis [70-74], Alzheimer's disease [75-
77], and Parkinson's disease [78-83], but whether TNF sig-
naling actively contributes to or limits neuronal injury in
these disorders has yet to be established. A number of pre-
clinical and clinical studies in various disease models and
in chronic neurodegenerative conditions suggest that tar-
geting TNF action in the brain may be an attractive dis-
ease-modifying strategy to slow progression or attenuate
severity of the disease and are discussed in sections below.
TNF inhibitors
Endogenous TNF inhibitors
A number of endogenous mechanisms limit TNF activity
during inflammatory responses as part of resolution of
those responses (reviewed in [84]). Identified endog-
enous inhibitors of TNF include prostaglandins and cyclic
AMP which limit TNF production and glucocorticoids
which are produced when TNF levels are high by activa-
tion of the hypothalamus pituitary adrenal axis to inhibit
TNF production [84-88]. Anti-inflammatory cytokines
including IL-10, IL-13 and IL-4 can inhibit TNF produc-
tion [89-92]. TACE cleaves tmTNF to generate solTNF and
it can also cleave TNF receptors to generate solTNFRs
which can bind solTNF in the circulation. In fact, soluble
forms of TNF receptors were first identified in urine and
their discovery lead to the development of anti-TNF anti-
body-based biologics [93-96]. Efferent activity of the
vagus nerve has also been shown to inhibit TNF produc-Journal of Neuroinflammation 2008, 5:45 http://www.jneuroinflammation.com/content/5/1/45
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tion through cholinergic activation of muscarinic recep-
tors [97-99].
Biologics
A number of protein-based TNF inhibitors which we will
refer to as biologics are available or currently under devel-
opment (Table 1), and a subset of these have been
approved for use in the treatment of peripheral autoim-
mune disorders including rheumatoid and juvenile arthri-
tis, ankylosing spondylitis, and Crohn's disease. Non-
selective biologic inhibitors include, but are not limited
to, infliximab, etanercept, and adalimumab, all of which
bind to soluble and tmTNF and prevent binding to TNF
receptors (Figure 1). Infliximab is a chimeric bivalent
Table 1: Selected TNF inhibitors.
Inhibitor 
(Trade name)
Class Description/Mode of 
Action
Specificity Developer and 
Stage
References
Adalimumab (Humira) Monoclonal antibody Humanized bivalent 
mouse IgG1 monoclonal 
antibody; binds to ligands
solTNF, tmTNF Abbott FDA approved 
2005
[100-103,179,180]
Apratastat Small molecule Dual TACE and MMP 
inhibitor
MMPs, TACE Wyeth Phase II 
terminated 2006
[121]
BMS-561392 Small molecule Specific TACE inhibitor TACE Bristol-Myers Squibb 
Phase II
[121]
Certolizumab 
(Cimzia)
Monoclonal antibody PEGylated antibody 
fragment
solTNF, tmTNF UCB FDA approved 
2008
[182]
CYT007-TNFQb Vaccine Anti-TNF vaccine TNF Cytos Biotechnology 
Phase I-IIa
[181]
DN-TNF (XPro1595) Inactive TNF variant TNF monomers 
engineered with point 
mutations to disrupt 
binding to TNFRs; 
exchange with solTNF to 
form dominant-negative 
heterotrimers; tmTNF-
sparing
solTNF Xencor Preclinical [105,106]
ESBA105 Antibody fragment Single-chain antibody 
fragment directed against 
TNF
TNF Esbatech (Zurich) 
Preclinical
[181]
Etanercept (Enbrel) Receptor biologic Human IgG fused to a 
dimer of the extracellular 
regions of TNFR2; binds 
to ligands
solTNF, tmTNF, 
Lympotoxin A
Amgen; Wyeth; 
Takeda FDA approved 
1998
[179,180]
Golimumab 
(CNTO148)
Monoclonal antibody Human monoclonal 
antibody; binds to ligands
solTNF, tmTNF Centocor, Schering-
Plough Phase III
[101]
GW333 Small molecule Dual TACE and MMP 
inhibitor
MMPs, TACE GlaxoSmithKline 
Preclinical
[121]
Infliximab (Remicade) Monoclonal antibody Murine-human Chimeric 
bivalent IgG1 monoclonal 
antibody; binds to ligands
solTNF, tmTNF Centocor Schering-
Plough FDA approved 
1998
[179,180]
Lenercept Receptor biologic Dimeric TNFR1 receptor 
extracellular domain fused 
to a human IgG1heavy 
chain fragment; binds to 
ligands
solTNF, tmTNF, 
Lympotoxin A
Roche Phase III 
terminated
[101,131,183]
Minocycline Small molecule Broad-spectrum 
tetracycline antibiotic; 
inhibits synthesis of TNF 
and other inflammatory 
mediators
solTNF, tmTNF, 
MMPs, COX-2, 
prostaglandin E2
Off patent [110-117]
tgAAC94 Gene therapy AAV vectors containing 
the TNFR2:Fc fusion
solTNF, tmTNF, 
Lympotoxin A
Targeted Genetics 
Phase I-II
[184]
Thalidomide Small molecule Immunomodulatory drug; 
increases degradation of 
mRNA of a number of 
inflammatory genes
TNF, COX-2, IL-1β, 
TGF-β, IL-12 and IL-6.
Celgene Corporation 
FDA approved 1998
[118,119]
Abbreviations: solTNF, soluble tumor necrosis factor; tmTNF, transmembrane tumor necrosis factor; TACE, tumor necrosis factor alpha 
converting enzyme; MMP, matrix metalloprotease; DN-TNF, dominant-negative tumor necrosis factor; TNFR, tumor necrosis factor receptor; 
COX-2, cyclo-oxygenase-2; IL1-β, interleukin-1beta; TGF-β, transforming growth factor beta; IL-12, interleukin-12; IL-6, interleukin-6.Journal of Neuroinflammation 2008, 5:45 http://www.jneuroinflammation.com/content/5/1/45
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IgG1 monoclonal antibody composed of a human con-
stant region and murine variable regions, adalimumab is
a humanized bivalent mouse IgG1 monoclonal antibody,
and etanercept is a fusion protein comprised of human
IgG fused to a dimer of the extracellular regions of TNFR2.
A number of important differences exist between TNF
inhibitors in their mode of action and specificity that are
worth noting (Table 1). Infliximab and adalimumab, by
virtue of being IgGI antibodies, can activate complement
and bind Fc Receptor and they also can bind both mono-
meric and trimeric solTNF whereas etanercept, like
TNFR2, only binds TNF trimers, however all three inhibi-
tors bind tmTNF and therefore inhibit signaling through
both TNF receptors [100-103]. Another difference
between etanercept and infliximab and adalimumab is
the ability of etanercept to neutralize lymphotoxin, a
property that is shared by its parent receptor TNFR2
[100,104]. In addition to these approved inhibitors sev-
eral similar antibody and receptor based TNF inhibitors
are currently or were previously under clinical investiga-
tion including lenercept, a dimeric TNFR1 receptor extra-
cellular domain fused to a human IgG1 heavy chain
fragment, and the fully human monoclonal antibody
golimumab (Table 1).
A new class of anti-TNF biologic with a dominant-nega-
tive (DN) mechanism of action has emerged and was
developed using structure-based computational design
leading to the generation of TNF variants referred to as
DN-TNFs which are able to exchange with native soluble
Schematic of TNF inhibitors and their mode of action Figure 1
Schematic of TNF inhibitors and their mode of action. Receptor (i.e. etanercept, lenercept) and antibody based (i.e. inf-
liximab, adalimumab, golimumab) anti-TNF biologics inhibit both solTNF and tmTNF. TNF variants (DN-TNFs) exchange with 
native solTNF monomers to form heterotrimers with drastically reduced abilities to bind TNF receptors, making them selec-
tive for solTNF signaling inhibition. Small molecule inhibitors of TNF signaling include minocycline which decreases TNF syn-
thesis, thalidomide which enhances degradation of TNF mRNA, and TACE inhibitors which prevent TACE induced release of 
solTNF.
TACE
TNFR1
TNFR2
tmTNF
solTNF
Antibody and Decoy Receptor 
Biologics
DN-TNF
Thalidomide
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TACE inhibitor
Transcription
Translation
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TNF monomers to form heterotrimers (Figure 1) with
drastically reduced abilities to bind TNF receptors
[105,106]. Due to this novel mechanism of action, DN-
TNFs selectively inhibit solTNF and do not inhibit tmTNF
signaling [105,107]. The ability of DN-TNFs to be tmTNF-
sparing and solTNF-selective may be ideal in clinical con-
ditions where solTNF signaling mediates pathology, and/
or to ensure that the role of tmTNF in immune function is
not compromised.
Small molecule TNF inhibition
A small molecule TNF inhibitor that has been described is
composed of trifluoromethylphenyl indole and dimethyl
chromone moieties linked by a dimethylamine spacer
[108]. This small molecule inhibitor binds to trimerized
TNF and accelerates subunit dissociation to lead to a TNF
dimer/small molecule complex that can not bind to and
activate TNFR1 [108].
Immunomodulatory drugs with TNF inhibitory action
Less specific inhibitors of TNF include minocycline and
thalidomide which have been used in the treatment of
inflammatory conditions. Minocycline, a broad-spectrum
tetracycline antibiotic, has been shown to have both bac-
teriostatic and anti-inflammatory actions [109]. Minocy-
cline not only decreases TNF synthesis, but also inhibits
matrix metalloproteases, reduces COX-2 activity and pros-
taglandin E2 production, and attenuates apoptosis [110-
117]. Thalidomide is an immunomodulatory drug which
means it can attenuate a variety of cytokines and immune
cell-mediated responses. Thalidomide inhibits TNF
through enhanced degradation of TNF mRNA [118,119],
however is can also alter the expression of COX-2, IL-1β,
TGF-β, IL-12 and IL-6 to affect immune cell regulation
and migration separate from its TNF-dependent effects
(reviewed in [118]).
TACE inhibitors
Another method by which inhibition of soluble TNF pro-
duction can be achieved is by inhibition of TACE, the pro-
tease that cleaves and converts tmTNF into its circulating
form. TACE, a member of the ADAM (A Disintegrin And
Metalloproteinase protein) family of matrix metallopro-
teases, is the primary enzyme responsible for TNF shed-
ding  in vivo [120]. Unlike what has been possible to
achieve with anti-TNF biologics, development of orally
available brain-permeant TACE inhibitors has been suc-
cessful. TACE inhibitors are in various stages of clinical
development, but there are limitations with current inhib-
itors including non-specific inhibition of other matrix
metalloproteases, and inhibition of other TACE sub-
strates; both properties may lead to undesired side-effects.
Current TACE inhibitors include two small-molecule dual
TACE and MMP inhibitors, GW333 and apratastat (TMI-
005), and a more specific TACE inhibitor BMS-561392
(reviewed in [121]). Development of apratastat for the
treatment of rheumatoid arthritis was terminated after
phase II clinical trials due to lack of efficacy [122]. Other
TACE inhibitors including BMS-561392 have been
delayed from clinical trials due to the potential risk of
hepatoxicity resulting from the accumulation of tmTNF
and the inhibition of TNFR1 and TNFR2 shedding which
was demonstrated in rats treated with TACE inhibitors
(reviewed in [121]).
TNF in multiple sclerosis (MS)
Evidence that implicates TNF in the underlying pathology
of multiple sclerosis (MS) includes: the observation that
at autopsy MS patients have elevated TNF levels at the site
of active MS lesions [70]; reports that CSF and serum TNF
levels in individuals with MS are elevated compared to
unaffected individuals and TNF levels correlate to the
severity of the lesions [72,123,124]; and evidence that
peripheral blood mononuclear cells from MS patients just
prior to symptom exacerbation have increased TNF secre-
tion after stimulation compared to cells form the same
patients during remission [73,125]. These characteristics
of TNF involvement are shared with peripheral autoim-
mune diseases. Based on these strong clinical parameters
implicating TNF signaling in contributing to MS disease
severity, the effects of manipulation of the TNF pathway
were investigated in mouse models of MS. Specifically,
overexpression of TNF leads to demyelinating disease and
neutralization of TNF with anti-TNF antibodies or recep-
tor fusion proteins is protective in experimental autoim-
mune encephalomyelitis (EAE) transgenic mouse models
[126-130]. Logically, based upon promising results in
these animal models, lenercept, a dimeric TNFR1 receptor
extracellular domain fused to a human IgG1heavy chain
fragment, was evaluated in MS patients. Unfortunately, a
phase II randomized, multi-center, placebo-controlled
study had to be halted due to a dose-dependent increase
in MS attack frequency and a trend towards increased
attack duration and severity [131]. Although the reasons
for unanticipated failure were not immediately clear, the
failed lenercept clinical trial served to prompt further
investigations into the action of TNF in nerve myelination
in animal models of MS and in transgenic mice with alter-
ations in TNF and its receptors. Subsequently, TNFR1 sig-
naling has been demonstrated to mediate nerve
demyelination whereas TNFR2 signaling appears to be
crucial for remyelination in the cuprizone mouse model
of MS. Specifically, it was shown that the absence of TNF
resulted in delayed remyelination, depletion of the oli-
godendrocyte progenitors, and reduction in mature astro-
cytes after cuprizone withdrawal with TNFR2 expression
alone being sufficient to restore oligodendrocyte regener-
ation [132]. Interestingly, the importance of TNF signal-
ing in mediating nerve demyelination was found to occur
independently of the adaptive immune response as theJournal of Neuroinflammation 2008, 5:45 http://www.jneuroinflammation.com/content/5/1/45
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Tg6074 line of TNF overexpressing mice, even when back-
crossed to mice deficient in CD4 (to ablate CD4+ lym-
pocytes),  β2-microglobulin (MHC I restricted T
lymphocytes), immunoglobulin μ (Ig+ lymphocytes), or
Rag-1 (T Cell receptor and Ig positive lymphocytes), still
develop primary demyelination to the same extent as
mice with an intact adaptive immune response [133].
These important findings in pre-clinical models have clin-
ical implications and suggest that inhibition of tmTNF/
TNFR2 signaling by lenercept was the molecular basis for
the worsening symptoms in MS patients. Experiments to
block solTNF/TNFR1 signaling with the solTNF-selective
DN-TNF inhibitors in the cuprizone model should yield
further support for this hypothesis. Transgenic animal
models in which tmTNF is expressed exclusively demon-
strated that tmTNF, in the absence of solTNF, suppresses
EAE disease onset and progression, while still maintaining
the ability of TNF signaling to suppress autoimmune
properties [134,135]. This ability of tmTNF to maintain
immune functions such as self-tolerance and resistance to
infection while limiting other TNF functions including
primary demyelination and oligodendrocyte apoptosis
[135] opens the possibility of selective inhibition of
solTNF/TNFR1 signaling as a therapeutic strategy to pre-
vent relapsing-remitting MS in patients afflicted with this
chronic inflammatory disease of the nervous system.
TNF in ischemia (stroke) models
There is conflicting evidence concerning the role of TNF in
ischemia (stroke) models (reviewed in [136]). For exam-
ple, TNF action has been inhibited in acute stroke through
intraventricular infusion of TNFR1 decoy receptor or anti-
TNF antibody, and through systemic administration of a
TACE inhibitor and both approaches resulted in reduced
ischemic injury [137-139]. However, hippocampal neuro-
genesis after ischemic injury resulting from stroke was
abolished when animals were treated with anti-TNF anti-
bodies two weeks after the ischemic event, suggesting that
TNF signaling may be necessary for repair processes after
an ischemic insult [140]. In addition, epileptic seizures
resulting from focal cerebral ischemia worsened in mice
deficient for TNF or TNF receptors, further suggesting that
TNF signaling is important for hippocampal function fol-
lowing ischemic injury [141]. The mechanism of TNF-
induced protection from epileptic development was
investigated in TNF and TNF receptor transgenic mouse
models. Specifically, astrocyte restricted overexpression of
TNF or intrahippocampal injection of TNF was found to
reduce susceptibility to kainate-induced seizure activity,
whereas single TNFR2 or double TNFR1/TNFR2-deficient
mice displayed prolonged seizure activity, implicating
TNFR2 and tmTNF signaling in protection against seizure
[142]. In summary, studies with TNF antibodies in stroke
and seizure models raise the interesting possibility that
TNF action through TNFR2 is important in hippocampal
repair and neurogenesis, and suggest that use of anti-TNF
drugs that do not spare TNFR2-dependent signaling may
result in untoward effects in this brain region.
TNF in Parkinson's disease (PD)
As in many other neurodegenerative diseases, TNF and
solTNFR1 levels are elevated in cerebrospinal fluid and
tissues of PD patients as well as in postmortem PD brains
with the highest TNF levels present in areas that have the
greatest loss of dopaminergic neurons [78-81]. Neverthe-
less, the importance of TNF signaling in contributing to
DA neuron dysfunction and death has only recently been
appreciated. In animal models of PD increased TNF
mRNA and protein are detectable in the midbrain within
hours of in vivo administration of a neurotoxic dopamine
analog, 6-hydroxydopamine (6-OHDA) [143], the mito-
chondrial complex I inhibitor 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) [144-146], and the bacterial
endotoxin lipopolysaccharide (LPS) [147]. In MPTP-
treated non-human primates, serum TNF levels have been
reported to remain elevated up to one year after a single
MPTP injection [148]. Multiple studies indicate that TNF
is highly toxic to dopaminergic neurons in both in vitro
primary cultures [149-151] and in vivo [152,153]. The
strongest genetic evidence implicating TNF in initiation
and progression of PD is that a polymorphism (-1031 C)
in the TNF promoter that drives transcriptional activity
and results in higher than normal TNF production is over-
represented in a cohort of Japanese early-onset PD
patients compared to late-onset PD patients and unaf-
fected controls [154]. Importantly, this -1031 C polymor-
phism has been associated with PD risk in an additional
study [155]. A second polymorphism in the TNF gene pro-
moter (-308 G/A) that results in elevated serum TNF levels
has also been found to be over-represented in early onset
sporadic PD [156,157]. Lastly, TNFR1 polymorphisms
TNFR1-609 and TNFRI+36 have been found to be signifi-
cantly decreased in PD patients [156]. In summary, the
association of TNF and TNFR1 polymorphisms with PD
risk strongly suggests involvement of TNF signaling in PD
progression. Meta-analyses will be needed to assess over-
all genetic association of TNF with PD risk.
Genetic approaches to investigate the role of TNF signal-
ing in the nigrostriatal pathway have involved use of mice
deficient in TNF and TNFRs but have yielded conflicting
results. In some studies TNFR1 or TNFR2 single-knockout
mice or double receptor deficient mice are not protected
from MPTP-induced striatal terminal damage or nigral
dopaminergic neuron loss [144,158]; whereas in other
studies receptor double-knockout mice have less striatal
damage than non-transgenic mice [145,159]; and in mice
lacking TNF MPTP-induced striatal dysfunction is
reduced, but dopaminergic neuron loss is not [146]. Dif-
ferent extents of MPTP lesioning may account for the con-Journal of Neuroinflammation 2008, 5:45 http://www.jneuroinflammation.com/content/5/1/45
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flicting results regarding the role of TNF and its receptors
in contributing to dopaminergic neuron loss.
Use of non-specific TNF inhibitors including thalido-
mide, a potent anti-inflammatory and sedative, and
minocycline, a tetracycline antibiotic that inhibits TNF
synthesis, has also been investigated in MPTP intoxication
paradigms in mice and in intranigral LPS rat models of PD
with protective outcomes in some [146,160] but not all
studies [161]. Due to potential genetic compensation
and/or TNF-independent anti-inflammatory effects of
these compounds, the direct role of TNF in dopaminergic
neuron death could not be established but was certainly
inferred. Only recently, a direct role for solTNF signaling
in mediating the in vivo degeneration of DA neurons in
both the 6-OHDA oxidative neurotoxin and chronic LPS
models of PD has been demonstrated by the ability of
dominant-negative (DN) TNF inhibitors or a lentivirus
encoding DN-TNF to attenuate nigral DA neuron loss
when delivered intranigrally [162,163]. In summary,
combined evidence from histopathologic, epidemiologic,
and pharmacologic studies supports a role for TNF in elic-
iting dopaminergic neuron loss and nigrostriatal degener-
ation, suggesting TNF neurotoxicity may underlie the
progressive loss that occurs in humans with PD.
TNF in Alzheimer's disease (AD)
The first indication of a contribution for TNF signaling in
AD was the presence of TNF at amyloidogenic plaques in
post-mortem analysis of AD brains [164]. In pre-clinical
studies, transgenic Tg2576 mice which overexpress a
mutated form of human amyloid precursor protein (APP)
and develop amyloid plaque pathology display elevated
TNF levels around fibrillar plaques consistent with find-
ings in human tissue [165-167]. The localization of TNF
within plaques in both animal models and human brains
prompted investigations into genetic associations
between AD and TNF and its receptors. A genome-wide
screen found that three TNF polymorphisms (-308, -238
promoter polymorphisms and a 10.5 kb upstream micro-
satellite TNFa) which result in elevated TNF secretion,
formed a haplotype that was associated with AD [168].
However, others have found that these polymorphisms
increase the age of AD onset [169]. In addition to genetic
linkage with TNF, the genetic association between the TNF
receptors (TNFR1 and TNFR2) and AD was investigated.
Specifically, the genes for TNFR1 and TNFR2 reside on
chromosome 1p and chromosome 12p, respectively and
these regions show genetic linkage to late-onset AD; in
addition, a genetic polymorphism in exon 6 of the TNFR2
gene was associated with late-onset AD, while no signifi-
cant association was found between AD and three genetic
polymorphisms in the TNFR1 gene [170]. Although these
genetic studies implicate TNF and its receptors in modify-
ing AD risk, independent confirmation by additional
studies as well as meta-analyses of genetic association
studies will be needed to assess the overall genetic effect of
these TNF related genes on AD [171,172].
Other evidence of increased inflammation and elevated
TNF levels in AD pathology includes the dysregulation of
TNF levels and other pro-inflammatory cytokines in AD
patients and in transgenic mouse models of AD. Elevated
TNF levels appear to correlate with disease progression as
higher serum levels of TNF, as well as an increase in the
TNF/IL-1β ratio, are present in patients with severe AD
compared to individuals with mild-to-moderate disease
[76]. However, similar to the case with genetic linkage
studies, not all studies found differences in TNF levels
between mild and severe disease [76,173]. Transgenic
mouse models of AD have provided evidence that inflam-
mation and TNF contribute to disease progression and
onset. In three month old mice harboring three familial
AD-linked mutations (APPSwe, tauP301L, and PS1M146V)
which lead to accumulation of intraneuronal amyloid
immunoreactivity in regions that include entorhinal cor-
tex, elevated TNF mRNA levels were reported in the same
regions and correlated with the onset of cognitive deficits
in these mice [174,175]. Inhibition of solTNF signaling in
triple transgenic mice (APPSwe, tauP301L, and PS1M146V) by
either hippocampal infusion of DN-TNF inhibitors or
intracerebroventricular injection of a lentivirus encoding
DN-TNF reduced inflammation-induced accumulation of
C-terminal APP fragments in the hippocampus, cortex,
and amygdale. In triple (3xTgAD) transgenic mice lacking
TNFR1, exposure to chronic systemic inflammation did
not result in intraneuronal accumulation of amyloid
immunoreactivity, suggesting that solTNF/TNFR1 signal-
ing may be an important regulator of APP processing and
that pathological elevation of TNF may contribute to pre-
plaque pathology and acceleration of cognitive deficits
(McAlpine et al., under review). In support of this idea,
the contribution of TNFR1 signaling to AD pathogenesis
was recently shown in APP23 transgenic mice which over-
express APPKM670/671NL. In these transgenic mice, TNFR1
deletion reduces Aß pathology, microglia activation,
BACE1 activity, neuron loss, and memory deficits com-
pared to transgenic APP23 mice expressing normal levels
of TNFR1 [176]. Although far from conclusive, a recent
report of a single-center, open-label clinical pilot study
involving patients with mild-to-severe AD who received
semi-weekly perispinal infusion of the anti-TNF biologic
etanercept for six months claimed detectable improve-
ment of cognitive performance in patients who received
etanercept compared to those that received placebo, rais-
ing the interesting possibility that modulation of TNF sig-
naling peripherally or centrally may have effects on
cognitive performance in patients with AD [177]. These
observations are not surprising in light of published stud-
ies that demonstrate TNF is a potent glio-transmitter.Journal of Neuroinflammation 2008, 5:45 http://www.jneuroinflammation.com/content/5/1/45
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However, additional double-blinded placebo-controlled
studies will be needed to confirm these promising find-
ings.
Conclusions and considerations for the future
TNF exerts pleiotropic effects in the CNS and its role in
normal brain functions, in particular synaptic scaling, has
yet to be fully elucidated. While it is clear that solTNF is
toxic to dopaminergic neurons and compromises their
survival during chronic inflammatory stimuli in the ven-
tral midbrain, tmTNF and TNFR2 appear to have impor-
tant roles in myelination and may contribute to
hippocampal neurogenesis after ischemic injury. These
observations strongly suggest that one potential approach
to lessen adverse effects of anti-TNF therapies in the CNS
may be to selectively target TNFR1 signaling with local-
ized delivery of inhibitors which spare TNFR2-mediated
signaling. As solTNF signals preferentially through
TNFR1, selective inhibition of solTNF signaling may be
advantageous. This approach may allow efficient neutral-
ization of solTNF in the desired region (i.e. substantia
nigra) without eliciting collateral damage to TNFR2/
tmTNF-dependent processes in regions of the brain where
tmTNF has important homeostatic functions. An addi-
tional benefit to selective targeting of solTNF would be
sparing tmTNF-dependent functions in the immune sys-
tem, including proper development and maintenance of
immune cell populations as well as self-tolerance and
resistance to infectious agents (such as Mycobacterium and
Listeria). Given the growing evidence that TNFR2 may
antagonize TNFR1 signaling, a second strategy, which
may bestow beneficial effects and allow protection of neu-
ronal populations highly sensitive to solTNF/TNFR1-
mediated toxicity, may be to increase TNFR2 expression
levels through gene therapy. Lastly, it is important to note
that while brain-permeant small molecule inhibitors of
TNF, including the immunomodulatory drugs thalido-
mide and minocycline, may be attractive for CNS applica-
tions, their lack of selectivity for solTNF over tmTNF and
their inhibitory effects on other inflammatory mediators
may contribute to undesirable effects as TNF signaling
and other inflammatory cascades would be suppressed
globally in the CNS [178].
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